Log In
Print
BCIQ
Print
Print this Print this
 

PBI-1402

  Manage Alerts
Collapse Summary General Information
Company ProMetic Life Sciences Inc.
DescriptionChemoprotective activator of neutrophils
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAnemia
Indication DetailsTreat anemia in patients with myelodysplastic syndrome (MDS); Treat anemia resulting from chronic kidney disease; Treat chemotherapy-induced anemia (CIA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$59.0M

0

$59.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today